Research programme: malaria vaccines - Leidos Holdings/National Institute of Allergy and Infectious DiseasesAlternative Names: Circumsporozoite protein-based vaccine - Leidos/NIAID; CSP antigen - Leidos/NIAID; Plasmodium falciparum-based vaccines - Leidos/NIAID; Px 533; Reticulocyte-binding homologue 5-based vaccine - Leidos/NIAID; Rh5 antigen - Leidos/NIAID
Latest Information Update: 14 Apr 2015
At a glance
- Originator Leidos Holdings
- Developer Leidos Holdings; National Institute of Allergy and Infectious Diseases
- Class Parasitic vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Malaria